GW Pharma shares soar 9% premarket as Oppenheimer upgrades to outperform

GWPharma 一年股价上涨85%,大麻癫痫药物 Epidiolex 拉动整体业绩提升

2019-05-08 08:15:47 MarketWatch

本文共711个字,阅读需2分钟

GW Pharmaceuticals PLC shares GWPH, +4.05% soared 9% in premarket trade Tuesday, after Oppenheimer upgraded the stock to outperform from perform, after the company reported better-than-expected earnings along with positive results in a late-stage trial of its Epidiolex treatment. Epidilolex is the first cannabis-based drug to win approval from the U.S. Food and Drug Administration as a treatment for severe forms of childhood epilepsy. The drug is now being tested as a treatment for patients with seizures associated with tuberous sclerosis complex, or TSC. "While we await detailed data that may be shared at a medical conference, we update our probability of approval of the sNDA for TSC to 87% from 41% (filing expected in 4Q), and move to an Outperform rating and a price target of $234 (vs. $162)," Oppenheimer analyst Esther Rajavelu wrote in a note to clients. "We also like management's efforts to broaden the pipeline with open label studies of CBDV for autism spectrum disorder and Rett syndrome which may contribute to a diversified portfolio." Stifel analysts led by Paul Matteis raised their stock price target to $227 from $191 and said dinner with GW management after the earnings report "reaffirms our view that the Epidiolex launch to date, considering all of the variables that have led the product to beat consensus, is going about as well as one could've hoped." Matteis is also expecting the drug to be approved for TSC in 2019. The analyst raised his revenue forecast for Epidiolex for the second quarter to $49 million from $26 million. GW Pharma shares have gained 85% in the last 12 months, while the S&P 500 SPX, -0.99% has gained 10%.
GW Pharmaceuticals PLC 股份 GWPH ,+4.05% 周二,在 Oppenheimer 将其股价从表现中提升至跑赢大盘后,该公司在上市前交易中飙升了9%,此前该公司公布了好于预期的收益,并在 Epidelex 治疗的后期试验中取得了积极结果。伊维地洛是第一个获得美国食品和药物管理局批准的基于大麻的药物,用于治疗严重形式的儿童癫痫。该药物目前正作为一种治疗与结节性硬化症( TSC )相关的癫痫的药物进行试验。Oppenheimer 分析师 Esther Rajavelu 在给客户的一份报告中写道:“尽管我们正在等待可能在医学会议上共享的详细数据,但我们将 TSC 批准 sNDA 的可能性从41%(预计在4Q 提交的文件)提高到87%,并转向了 Outperformance 评级和234美元(相对于162美元)的价格目标。”“我们还希望管理层努力拓宽这一渠道,对自闭症谱系障碍和视网膜综合征的 CBDV 进行开放标签研究,这可能有助于多元化投资组合。”由 Paul Matteis 领导的 Stifel 分析师将其股价目标从191美元上调至227美元,并在财报公布后与 GW 管理层共进晚餐。“重申了我们的观点,即 Epipodilex 的推出迄今,考虑到所有导致该产品超出共识的变量,正在进行中,而且人们可能希望如此。”Matteis 还预计该药物将在2019年获得 TSC 的批准。分析师将 Epidelex 第二季度的营收预期从2600万美元上调至4900万美元。GWPharma 股价在过去12个月中上涨了85%,标准普尔500指数上涨了500 SPX ,-0.99% 上涨了10%。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文